Dosing Complete in Phase 2 Trial Evaluating Lymfactin for BC Treatment-Associated Lymphedema
News
Herantis Pharma has completed patient dosing in its Phase 2 trial evaluating the investigational gene therapy Lymfactin for secondary lymphedema — a common complication of breast cancer treatment caused by ... Read more